16 Total results for product and free and sample content found
Datamonitor Healthcare, Biomedtracker, Pharma...
By Hardik Patel 15 Jul 2019
Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019.
Scrip
By Joseph Haas 31 Oct 2017
Within weeks of its acquisition of Kite, Gilead is working to launch its first immuno-oncology drug, with a goal of training.
Topic immuno-oncology
Datamonitor Healthcare
By Colin White, Robert Jeng & Jolene Lau 19 Sep 2017
This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well
Topic immuno-oncology
Datamonitor Healthcare
By Dustin Phan 17 Sep 2017
Recently, Informa Pharma Intelligence conduced an insightful webinar regarding the current market landscape and outlook for immuno-oncology.
Topic immuno-oncology
Scrip
02 Aug 2017
The US FDA has approved BMS' Opdivo for previously treated patients with some forms of colorectal cancer, however direct competition from Merck's Keytruda may limit its success.
Topic immuno-oncology Cancer
Scrip
By Lucie Ellis 26 Jul 2017
Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.
Topic Cancer immuno-oncology Research & Development Strategy
Scrip
24 Jul 2017
As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.
Topic Cancer immuno-oncology
Scrip
By Joseph Haas 04 Jul 2017
Trying to catch up with peers in both immuno-oncology and NASH, the German pharma has assigned Sapountzis to lead its US business development efforts.
Topic Cancer immuno-oncology
Pink Sheet
By Francesca Bruce 06 Jun 2017
The clinical potential of immuno-oncology drugs does not seem to be reflected in approaches by health technology assessment bodies, with different interpretations of data.
Topic immuno-oncology
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: